SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
11 July 2022 - 10:00PM
SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, fully human
polyclonal antibodies without the need for human donors, today
announced the appointment of Rear Admiral (RADM), retired, Scott
Giberson, a former Assistant U.S. Surgeon General and two-star
admiral with the U.S. Public Health Service to SAB’s Board of
Directors, effective July 7, 2022. RADM Giberson retired after a
decorated career and 27 years of service. In 2018, the Military
Officers Association of America selected him as one of the “Top 100
Veterans in the Last 100 Years you Need to Know.”
Currently, RADM (ret.) Giberson is the President of AMI
Expeditionary Healthcare, a company that provides medical services
to international aid organizations, humanitarian concerns, the
private sector and government agencies in a wide range of remote
and challenging environments.
“RADM (ret.) Scott Giberson’s impressive career working in the
U.S. government combined with expertise in healthcare is a valuable
and welcomed addition to SAB’s Board of Directors,” said Samuel J.
Reich, Executive Chairman of SAB. “As SAB continues to develop and
harness our proprietary technology to address today’s most pressing
unmet medical needs, we look forward to RADM (ret.) Giberson’s
future contributions to the Board.”
RADM (ret.) Giberson served as the acting Deputy Surgeon General
of the United States (2013-2014), where he worked with the U.S.
Surgeon General to develop and deliver scientific information to
the public. In that role, he served as the Surgeon General’s
principal liaison with health leadership in the Department of
Defense, Department of Homeland Security, and Department of Health
and Human Services, among others. He held additional executive
positions as the Senior Advisor to the Office of Surgeon General,
Director of Commissioned Corps Headquarters, Chief Pharmacist of
the U. S. Public Health Service, and Senior Public Health Advisor
for Pacific Command’s Center of Excellence in Disaster Management
and Humanitarian Assistance. In 2014, he also served as overall
Commander of the Commissioned Corps’ Ebola Response in West
Africa.
“Ensuring high-quality care and services are provided to those
in need has been a cornerstone of my career,” said RADM (ret.)
Giberson. “SAB is poised to help address some of the world’s most
significant health needs, such as C. difficile and type-1 diabetes.
I am honored to join such an innovative company in their endeavors
to improve global public health.”
Early in his career, he worked in several Indian Health Service
(IHS) facilities where he was credentialed as a pharmacist and as a
mid-level provider in family medicine. He also served as the
Director of the IHS National HIV/AIDS Program and was a
contributing author to the President’s National HIV/AIDS
Strategy.
Beyond his remarkable career history, RADM (ret.) Giberson has
authored numerous articles and delivered more than 100 keynote
lectures on leadership, pharmacy, global health, and public health,
as well as multiple university commencements. He has been
interviewed on various TV and radio affiliates and serves on
several academic boards. Additionally, he has received multiple
service awards including the Defense Meritorious Service Medal and
the Surgeon General’s Medallion. In 2015, he received the
Presidential Unit Citation from President Obama in the Oval
Office.
RADM (ret.) Giberson graduated from Temple University and
University of Massachusetts/Amherst with a BS Pharm, MPH, and
graduate certificate in Health Emergencies in Large Populations. He
has received three honorary Doctoral degrees (one for his
pioneering work in interprofessional practice) and is a Fellow of
the Wharton Business School Executive Leadership Program.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage,
biopharmaceutical company advancing a new class of immunotherapies
leveraging fully human polyclonal antibodies with a focus on
building a leading immune and autoimmune disorders pipeline. SAB
has applied advanced genetic engineering and antibody science to
develop transchromosomic (Tc) Bovine™ that produce fully human
antibodies targeted at specific diseases, including infectious
diseases such as COVID-19 and influenza, immune and autoimmune
disorders including type 1 diabetes and organ transplantation, and
cancer. SAB’s versatile DiversitAb™ platform is applicable to a
wide range of serious unmet needs in human diseases. It produces
natural, specifically targeted, high-potency, human polyclonal
immunotherapies. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio/ and follow SAB on Twitter and
LinkedIn.
Forward-Looking Statements
Certain statements made in this press release that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally are
accompanied by words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect,” “should,” “would,”
“plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook”
and similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, including the development and
efficacy of SAB-195 (C. Diff), SAB-176 (Influenza), SAB-142 (Type 1
Diabetes & Immunology), SAB-185 (COVID-19), and our other
discovery programs; our cash runway into 2023; and potential future
government and third-party collaborations or funded programs. These
statements are based on the current expectations of SAB and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as, and must not be relied on, by any investor as a
guarantee, an assurance, a prediction or a definitive statement of
fact or probability. Actual events and circumstances are difficult
or impossible to predict, may differ from assumptions, and are
beyond the control of SAB. A further description of risks and
uncertainties can be found in the sections entitled “Risk Factors”
in SAB’s most recent Annual Report on Form 10-K, most recent
quarterly reports on Form 10-Q, and in other filings SAB makes with
the Securities and Exchange Commission, available at
https://www.sec.gov/. Except as otherwise required by law, SAB
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances, or otherwise.
CONTACTS
Investor Relations:SABIR@westwicke.com
Media Relations:SABPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jun 2024 to Jul 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jul 2023 to Jul 2024